Plain-English translation of NCT05451602 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new cancer medication called in people with advanced solid tumors, particularly those caused by changes in a gene called RET. The trial has two parts: first, researchers will find the safest and most effective dose, then they will test how well the medication works at that dose.
Some advanced cancers are driven by changes in the RET gene, and current treatment options are limited. This trial exists to see whether this medication can be an effective new option for people whose cancers have these specific genetic changes.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth at a dose determined by the research team, with regular visits to the clinic for blood tests, imaging scans, and check-ins about how you're feeling. The study involves multiple clinic visits over time, and you'll need to provide tumor tissue (either archived or a fresh biopsy) so researchers can understand how the treatment is working on your specific cancer.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Sunshine Lake Pharma Co., Ltd.
Enrollment target
~456 participants
Started
October 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.